Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

Journal of Experimental Medicine

Volumn 196, Issue 4, 2002, Pages 541-549

  Vicari, Alain P ^a   Chiodoni, Claudia ^b   Vaure, Céline ^a   Aït Yahia, Smina ^a   Dercamp, Christophe ^a   Matsos, Fabien ^a   Reynard, Olivier ^a   Taverne, Catherine ^a   Merle, Philippe ^c   Colombo, Mario P ^b   O'Garra, Anne ^a   Trinchieri, Giorgio ^a   Caux, Christophe ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSERM   (France)

Author keywords

Cancer; Immunosuppression; Immunotherapy; Interleukin 12; Toll like receptor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR ANTIBODY; LIPOPOLYSACCHARIDE; OLIGONUCLEOTIDE; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CD8-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; DENDRITIC CELLS; FEMALE; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; TUMOR CELLS, CULTURED;

EID: 0037136303     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20020732     Document Type: Article

References (33)

1. Dendritic cells and the control of immunity
2. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines
3. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
4. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
5. The dendritic cell and human cancer vaccines
6. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
7. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
8. Papillary carcinoma of the thyroid: Hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells
9. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
10. Dendritic cells as sensors of infection
11. The host-tumor immune conflict: From immunosuppression to resistance and destruction
12. Tumor escape from immune surveillance through dendritic cell inactivation
13. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice
14. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms
15. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type I responses to soluble antigen only in the presence of lipopolysaccharide
16. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants
17. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes
18. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
19. Mouse and human dendritic cell subtypes
20. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
21. A Toll-like receptor recognizes bacterial DNA
22. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
23. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity
24. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages
25. Endotoxin-induced maturation of MyD88-deficient dendritic cells
26. Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of Toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages
27. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
28. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
29. Immunostimulatory oligodeoxzynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
30. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
31. In vivo manipulation of dendritic cells to induce therapeutic immunity
32. Nk- and cd8(+) t cell-mediated eradication of established tumors by peritumoral injection of cpg-containing oligodeoxynucleotides
33. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs